Oseltamivir reduces duration and complications of influenza
the ONA take:
According to a new study published in the journal The Lancet, researchers at the University of Michigan, the University of Alabama, and the London School of Hygiene and Tropical Medicine have found that oseltamivir, a neuraminidase inhibitor, decreases the duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
For the meta-analysis, researchers identified clinical trials conducted between 1997 and 2001. The studies included over 4,300 patients with more than half being treated with oseltamivir for influenza.
Results showed that when patients took oseltamivir 75mg twice daily within 36 hours of developing at least two flu symptoms, oseltamivir decreased the duration of the flu by 21%.
Patients who took oseltamivir experienced symptom alleviation at 98 hours versus 123 hours for those who took placebo.
In addition, researchers found that 4.9% of those who took oseltamivir had respiratory complications compared with 8.7% of those who took placebo. Oseltamivir was also shown to reduce hospital admissions by 63%. In regard to safety, oseltamivir increased nausea and vomiting, but did not cause more neurological or psychological disorders than placebo.
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
Sign Up for Free e-newsletters
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Oncology Extended Care Clinic Reduced Urgent Cancer-Related ED Visits
- Cervical Cancer Outcomes Comparable With Adjuvant Chemotherapy, Chemoradiotherapy
- Hair Dyes and Cancer Risk (Fact Sheet)
- Taste Changes After Hematopoietic Stem Cell Transplant Affect QOL in Blood Cancers
- Hope, Optimism Reduce Psychological Distress in Advanced Cancer
- Risk for Long-Term Cardiovascular Disease Increased for Endometrial Cancer Survivors
- Mitomycin Extravasation Protocol
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Skipping the SICU Post Head and Neck Cancer Surgery May Improve Outcomes
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|